17 Nov 08 Enrollment In EMERALD 1 Complete, 3rd Of 4 Phase 3 Clinical Trials Of Hematide™ To Treat Anemia In Chronic Renal Failure Patients
Affymax, Inc. (Nasdaq:AFFY) today announced that enrollment has been completed in EMERALD 1, one of its Phase 3 clinical trials of its lead investigational therapy, Hematide™, which is being evaluated for the treatment of anemia in chronic renal failure patients. EMERALD 1 includes over 800 dialysis patients from over 90 sites in the United States.
(more…)
Tags: Affy, Anemia, Chronic Renal Failure, Clinical Trials, Dialysis Patients, Emerald, Failure Patients, Hematide, Lead, Nasdaq, Phase 3, Treatment Failure, Treatment Of Anemia, United States
17 Nov 08 Enrollment In EMERALD 1 Complete, 3rd Of 4 Phase 3 Clinical Trials Of Hematide™ To Treat Anemia In Chronic Renal Failure Patients
Affymax, Inc. (Nasdaq:AFFY) today announced that enrollment has been completed in EMERALD 1, one of its Phase 3 clinical trials of its lead investigational therapy, Hematide™, which is being evaluated for the treatment of anemia in chronic renal failure patients. EMERALD 1 includes over 800 dialysis patients from over 90 sites in the United States.
(more…)
Tags: Affy, Anemia, Chronic Renal Failure, Clinical Trials, Dialysis Patients, Emerald, Failure Patients, Hematide, Nasdaq, Phase 3, Treatment Failure, Treatment Of Anemia, United States
05 Nov 08 Medgenics Announces Encouraging Preliminary Data For Phase I/II Clinical Trial Of EPODURE In Renal Anemia
Medgenics (AIM: MEDG), is pleased to announce encouraging preliminary data for its Phase I/II clinical trial. The landmark Phase I/II clinical trial of Medgenics’ EPODURE Biopump, for providing sustained treatment of anemia in subjects with chronic kidney disease, is underway.
(more…)
Tags: Aim, Anemia, Chronic Kidney Disease, Clinical Trial, Landmark, Treatment Of Anemia
05 Nov 08 Renal Anemia - Medgenics Announces Encouraging Preliminary Data For Phase I/II Clinical Trial Of EPODURE
Medgenics (AIM:MEDG), is pleased to announce encouraging preliminary data for its Phase I/II clinical trial. The landmark Phase I/II clinical trial of Medgenics’ EPODURE Biopump, for providing sustained treatment of anemia in subjects with chronic kidney disease, is underway.
(more…)
Tags: Aim, Anemia, Chronic Kidney Disease, Clinical Trial, Landmark, Medgenics, Treatment Of Anemia
05 Nov 08 Affymax Completes Enrollment In PEARL 2, 2nd Of 4 Phase 3 Clinical Trials Of Hematide To Treat Anemia In Chronic Renal Failure Patients
Affymax, Inc. (Nasdaq:AFFY) today announced that enrollment has been completed in the second of four Phase 3 clinical trials of its lead investigational therapy, Hematide™, which is being evaluated for the treatment of anemia in chronic renal failure patients. PEARL 2 (Phase 3 Evaluation of Hematide for Anemia Correction in Chronic Renal Failure) is fully enrolled with over 490 non-dialysis patients from over 60 sites in the United States and Europe.
(more…)
Tags: Affy, Anemia, Chronic Renal Failure, Clinical Trials, Dialysis Patients, Europe, Failure Patients, Hematide, Lead, Nasdaq, Phase 3, Treatment Failure, Treatment Of Anemia, United States
